About Biofortuna
Biofortuna is a Healthcare company based in Birkenhead (United Kingdom) founded in 2008 by Katherine Douglas, Nanette Douglas, and Rachel Douglas. It operates as a provider of manufacturing services for immunoassays, molecular diagnostics, and regulatory services. Biofortuna has raised $21.58 million across 9 funding rounds from investors including Enterprise Ventures, Foresight Group and Merseyside Special Investment Fund. The company has 32 employees. Biofortuna has completed 1 acquisition, including Cryoniss. Biofortuna was last valued at $476.6 million in August 2018. Its focus areas include Biopharma Outsourcing, Diversified and Biologics. Its legal entity is BIOFORTUNA LIMITED. Its competitors include Novartis, Catalent, Surrozen, Biotage and Curia and 4 more; 4 of its 9 listed competitors have raised funding.
Company details
Biofortuna was established in 2008 in Birkenhead, United Kingdom, within the biotechnology sector. Operations focus on contract manufacturing for immunoassays and molecular diagnostics, complemented by regulatory services. These activities support diagnostic product development and compliance needs for clients in healthcare and life sciences. The company is led by co-founders Katherine Douglas, Nanette Douglas, and Rachel Douglas.
- Headquarters Birkenhead, United Kingdom
- Employees 32
- Founders Katherine Douglas, Nanette Douglas, Rachel Douglas
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website biofortuna.com
- Social LinkedIn X
- Legal Name Biofortuna Limited
- Date of Incorporation 26 Feb, 2008
- Jurisdiction DEESIDE, WALES
- Annual Revenue$1.44 M (USD)-12as on Mar 31, 2018
- Net Profit-$1.34 M (USD)-32as on Mar 31, 2018
- EBITDA-$1.57 M (USD)-17as on Mar 31, 2018
- Total Equity Funding$21.58M (USD)
in 9 rounds
- Latest Funding Round$303.19K (USD), Grant
Feb 2026
- InvestorsEnterprise Ventures
& 5 more
- Employee Count32
- Investments & Acquisitions
Funding Insights of Biofortuna
Biofortuna has successfully raised a total of $21.58M across 9 strategic funding rounds. The most recent funding activity was a Grant round of $303.19 thousand completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $21.58M
- Total Rounds 9
- Last Round Grant — $303,192
- First Round $1.64M
(May 2010)
- Investors Count 6
All 9 funding rounds of Biofortuna with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $303,192 | Grant | – | – | |
| Mar 2021 | – | Series A | – | – | – |
| Aug 2018 | $4.5M | Series A | $476.6M | – | – |
| Jul 2017 | $2.09M | Series A | $134.19M | – | |
| Jan 2015 | $2.27M | Series A | – | – | |
| Apr 2014 | $756,000 | Series A | $••••• | – | – |
| Aug 2013 | $2.02M | Series A | – | – | |
| Mar 2012 | $8.3M | Series A | – | – | |
| May 2010 | $1.64M | Seed | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Aug 2018 | $476.6M | •••••••• |
| Jul 2017 | $134.19M | •••••••• |
| Apr 2014 | $••••• | •••••••• |
| Mar 2012 | $••••• | •••••••• |
Full valuation and stage history of Biofortuna
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $476.6M (Aug 2018). 6 investors in total: 5 institutional and 1 angel.
Investors in Biofortuna
Biofortuna has secured backing from 6 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Enterprise Ventures, Foresight Group and Merseyside Special Investment Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A fund focused on supporting SMEs with alternative finance. | – | msif.co.uk | Liverpool, United Kingdom | |
Early and Growth stage Venture Debt firm that does debt investments in the UK | 1982 | evgroup.uk.com | Preston, United Kingdom | |
Investment solutions are provided by Catapult Ventures for growth. | – | catapult-ventures.com | Leicester, United Kingdom | |
Foresight Group is engaged in sustainable investment management. | 1984 | foresightgroup.eu | - | |
- | – | gov.wales | - | |
DW David Whitcombe | Angel investor in Indian startups, focused on tech and innovation. | – | unknown_39f2e7fce2f5400fa | - |
Investor details for Biofortuna
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biofortuna
3 people are tracked at Biofortuna (3 in leadership); the tracked headcount is 32.
| Name | Role | Group |
|---|---|---|
Katherine Douglas | Co-Founder | Leadership |
Nanette Douglas | Co-Founder | Leadership |
Rachel Douglas | Co-Founder | Leadership |
Complete people profiles for Biofortuna
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biofortuna
Biofortuna has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cryoniss.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of biobanking services for life sciences industries | cryoniss.com | Macclesfield, United Kingdom | 2018 | May 2024 | •••• |
Complete acquisition details for Biofortuna
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Biofortuna
5 dated milestones of Biofortuna across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Biofortuna is founded.
- Funding First funding round of $1.6M.
- Milestone Reaches Minicorn status.
- Acquisition Acquires Cryoniss.
- Funding Latest funding round, Grant, of $303K.
Competitors of Biofortuna
Biofortuna has 9 listed competitors in our database, 4 of them funded. They include Novartis, Catalent, Surrozen, Biotage and Curia, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| novartis.com | 1996 | Basel, Switzerland | – | 97 | R&D focused on manufacturing of drugs for multiple therapeutic areas | |
| catalent.com | 2007 | Somerset, United States | – | 9,390 | CDMO offering drug and biologics development services | |
| surrozen.com | 2016 | San Francisco, United States | $133M | 80 | Selective Wnt agonists are developed for human tissue regeneration. | |
| biotage.com | 2009 | Uppsala, Sweden | – | – | Organic synthesis, analytical, and peptide chemistry services for drug discovery and development | |
| curiaglobal.com | 1991 | Albany, United States | – | 1,918 | Drug research, development, testing, and consulting services are provided. | |
| wuxibiologics.com | 2008 | Shanghai, China | – | 257 | Protein therapeutics are developed and manufactured by WuXi Biologics. | |
| amplify-bio.com | 2021 | Hilliard, United States | $229.75M | – | Provides contract research, development, and manufacturing services for biologic drugs. | |
| tirupatigroup.co.in | 1980 | Paonta Sahib, India | $50.42M | 1,827 | Pharmaceutical products are manufactured under contract by Tirupati Medicare. | |
| indapta.com | 2016 | Seattle, United States | $72.5M | – | Limited information available |
Detailed competitors of Biofortuna
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biofortuna
The website of Biofortuna (biofortuna.com) receives about 2.2K visits a month.
- Monthly visits2.2K
▼ 26.4% vs previous month
Websites whose visitors overlap most with Biofortuna. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sbsgenetech.com | sbsgenetech.com | 100% | – | #3,899,505 | – |
Top companies in Biopharma Outsourcing & Drug Delivery
10 companies that operate in the same segment as Biofortuna (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biofortuna
Complete news archive for Biofortuna
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biofortuna
Biofortuna was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Biofortuna is headquartered in Birkenhead, United Kingdom. It is registered at Birkenhead, Merseyside, United Kingdom.
Biofortuna is a funded company, having raised a total of $21.58M across 9 funding rounds to date. The company's 1st funding round was a Seed of $1.64M, raised on May 2010.
Biofortuna has 32 employees.
Annual revenue of Biofortuna is $1.44M as on Mar 31, 2018.
Biofortuna was established in 2008 in Birkenhead, United Kingdom, within the biotechnology sector. Operations focus on contract manufacturing for immunoassays and molecular diagnostics, complemented by regulatory services. These activities support diagnostic product development and compliance needs for clients in healthcare and life sciences. The company is led by co-founders Katherine Douglas, Nanette Douglas, and Rachel Douglas.
Biofortuna has made 1 acquisition, including Cryoniss.
Biofortuna has 6 investors. Key investors include Enterprise Ventures, Foresight Group, Merseyside Special Investment Fund, Catapult Ventures, and David Whitcombe.
The valuation of Biofortuna is $476.6M as of Aug 2018.
Biofortuna operates through Biofortuna Limited.